Chairman Joshua Boger Discloses $3M Investment in Private Placement, Now Owns 20% of CervoMed
CRVO is trading near its 52-week low of $2.13 (15% above the low) on elevated volume (2.2× avg).
Summary
CervoMed's Chairman and 10% owner, Joshua S. Boger, disclosed a $3 million investment in the company's recent private placement, increasing his beneficial ownership to 20% and signaling strong conviction after recent financial challenges.
Key Events · Ownership and Investor Activity · CRVO
-
Chairman's $3M Investment
Joshua S. Boger's trust invested approximately $3 million in CervoMed's recent private placement, purchasing 955,414 units.
-
Increased Ownership
Boger's beneficial ownership now stands at 2,204,143 shares, representing 20.0% of the company's outstanding common stock.
-
Strategic Capital Infusion
This investment was part of a $10.5 million private placement that extended CervoMed's cash runway into Q2 2027, following previous "going concern" warnings.
-
Warrant Details
The investment included common stock, Series B warrants (exercise price $3.32), and Series C warrants (exercise price $3.14), subject to a 19.99% ownership limitation on exercise.
Analysis · CRVO · Life Sciences
This Schedule 13D/A details Chairman Joshua S. Boger's significant participation in the recent $10.5 million private placement, where his trust invested approximately $3 million. This substantial investment, which includes common stock and warrants, increases his beneficial ownership to 20% of the company. This strong vote of confidence from a key insider follows recent "going concern" warnings and is critical for extending the company's cash runway.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRVO was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23M. The 52-week trading range was $2.13 to $13.13. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.